19.84
-1.05%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shenzhen Weiguang Biological Products Co
Its shares trade on Shenzhen under the ticker 002880.SZ. It has been listed since 16 June 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.27bn and net income of CN¥246.3m. At that date it held total assets of CN¥3.74bn and shareholders' equity of CN¥2.41bn.
Shenzhen Weiguang Biological Products Co., Ltd. engages in the manufacturing, research and development of drug and blood products. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2017-06-16. The Company’s primary products are blood products, including the human serum albumin, human immunoglobulin, intravenous human immunoglobulin, freeze-dried intravenous human immunoglobulin, hepatitis B human immunoglobulin, Rabies immunoglobulin, tetanus immunoglobulin, histamine human immunoglobulin, and human fibrinogen. The firm mainly operates its businesses in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Jun 2017
- Employees
- 796
- Website
- szwg.com ↗
Leadership
Pay as last reported
- Mr. Zhan ZhangChairman of the BoardCN¥1.1m
- Mr. Guanqun ChenChief Financial Officer, Director, since 2024
- Mr. Jianjun JinChief Marketing Officer, Secretary of the Board
- Ms. Caiping GuoGeneral Manager, Director, since 2013CN¥982,800
- Mr. Wenjie XieDeputy General Manager, Staff Elected Director, since 2024
- Mr. Ligang LiDirector
- Mr. Xian'en ZhangDirector
- Ms. Juan HuangIndependent Director
- Ms. Yanmei WangIndependent DirectorCN¥4,200
- Mr. Jianping ZhangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shenzhen Weiguang Biological Products Co Ltd manufactures human serum albumin and immunoglobulin products.
- The company employs 796 full-time employees in Shenzhen, Guangdong.
- Shenzhen Weiguang's primary products include intravenous human immunoglobulin and hepatitis B immunoglobulin.
Weaknesses
- The company operates primarily in the domestic market of China.
- Shenzhen Weiguang's business is limited to blood products without diversification.
- The firm has no international presence beyond China's domestic market.
Opportunities
- Expanding into international markets for blood products could increase revenue.
- Growing demand for human fibrinogen in China's healthcare sector presents opportunities.
- The domestic market in China offers potential for increased sales of immunoglobulin products.
Threats
- Competition from domestic biotechnology firms in China may impact market share.
- Regulatory changes in China's healthcare sector could affect operations.
- Dependence on the domestic market exposes the company to regional economic fluctuations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.